NeuroSense Therapeutics
NRSN
5 hedge funds and large institutions have $132K invested in NeuroSense Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 5 closing their positions.
1.23% less ownership
Funds ownership: 1.86% → 0.63% (-1.2%)
29% less funds holding
Funds holding: 7 → 5 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
82% less capital invested
Capital invested by funds: $733K → $132K (-$601K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$111K |
| 2 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$2.05K |
| 3 |
Morgan Stanley
New York
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$261K |
| 2 |
Citigroup
New York
|
-$168K |
| 3 |
Millennium Management
New York
|
-$68K |
| 4 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
-$47.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $97K | +$111K | +54,300 | New |
|
|
VPIM
2
Vanguard Personalized Indexing Management
Oakland,
California
| $30K | -$47.3K | -23,102 | -58% |
|
3
UBS Group
Zurich,
Switzerland
| $3K | -$23.8K | -11,601 | -86% |
|
|
4
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $2K | +$2.05K | +1,000 | New |
|
|
5
Jane Street
New York
| – | -$261K | -77,249 | Closed |
|
|
6
Citigroup
New York
| – | -$168K | -49,744 | Closed |
|
|
7
Millennium Management
New York
| – | -$68K | -20,259 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$33K | -9,794 | Closed |
|
|
CS
9
Clear Street
New York
| – | -$24K | -7,157 | Closed |
|
|
10
Morgan Stanley
New York
| – | +$8 | +4 | New |
|
NRSN Hedge Fund Activity: Q3 2022 in Review
5 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q3 2022, worth a combined $132K — down 82% from $733K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NRSN and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $111K. The largest seller was Jane Street, exiting entirely with an estimated $261K sold.
- 5 institutional investors held NeuroSense Therapeutics (NRSN) as of Q3 2022, down from 7 in Q2 2022.
- Funds reported $132K of NeuroSense Therapeutics stock for Q3 2022, down 82% quarter-over-quarter.
- 3 funds opened new NeuroSense Therapeutics positions in Q3 2022 and 5 closed out, a net change of -2 holders.
- The largest NeuroSense Therapeutics buyer in Q3 2022 was Renaissance Technologies, an estimated $111K added.
- The largest NeuroSense Therapeutics seller in Q3 2022 was Jane Street, an estimated $261K sold.
Based on aggregated 13F filings for Q3 2022.